Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24507201 | 0.86 | PPARG (0.43) | ALOX15HIF1AEPAS1PPARGPPARA | |
| SCHEMBL22459188 | 0.82 | MEN1 (0.44) | ALOX15HIF1AEPAS1 | |
| SCHEMBL1832904 | 0.78 | MEN1 (0.36) | — | |
| SCHEMBL5777587 | 0.75 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL19232109 | 0.72 | CNR2 (0.42) | — | |
| SCHEMBL19387999 | 0.71 | CNR2 (0.35) | ALOX15HIF1AEPAS1 | |
| SCHEMBL19441058 | 0.71 | TAAR1 (0.50) | — | |
| SCHEMBL186541 | 0.70 | CNR1 (0.42) | — | |
| SCHEMBL18519140 | 0.69 | KMT2A (0.45) | — | |
| SCHEMBL15996608 | 0.69 | CNR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | NLN, GAP43, PSEN2 | ALOX15 3072/4885HIF1A 4577/4885EPAS1 2243/4885 |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | GAP43, NLN, SNAP29 | ALOX15 2430/4885HIF1A 4522/4885EPAS1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.